BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · IEX Real-Time Price · USD
1.165
-0.005 (-0.43%)
Jul 22, 2024, 11:34 AM EDT - Market open
BioXcel Therapeutics Employees
BioXcel Therapeutics had 74 employees as of December 31, 2023. The number of employees decreased by 109 or -59.56% compared to the previous year.
Employees
74
Change (1Y)
-109
Growth (1Y)
-59.56%
Revenue / Employee
$23,730
Profits / Employee
-$2,068,216
Market Cap
43.54M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
NeueHealth | 1,252 |
Qilian International Holding Group | 298 |
Fortress Biotech | 186 |
Lucid Diagnostics | 70 |
OncoCyte | 46 |
Envoy Medical | 34 |
Matinas BioPharma Holdings | 32 |
Regencell Bioscience Holdings | 12 |
BTAI News
- 6 days ago - BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film - GlobeNewsWire
- 7 weeks ago - BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia - GlobeNewsWire